214 related articles for article (PubMed ID: 23733001)
1. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
Sasaki K; Lu G; Saliba RM; Bashir Q; Hosing C; Popat U; Shah N; Parmar S; Dinh Y; Ahmed S; Shpall EJ; Kebriaei P; Shah JJ; Orlowski RZ; Champlin R; Qazilbash MH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1227-32. PubMed ID: 23733001
[TBL] [Abstract][Full Text] [Related]
2. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
[TBL] [Abstract][Full Text] [Related]
3. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
4. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
[TBL] [Abstract][Full Text] [Related]
5. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
8. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Fonseca R; Blood EA; Oken MM; Kyle RA; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Hoyer JD; Harrington D; Kay NE; Van Ness B; Greipp PR
Blood; 2002 May; 99(10):3735-41. PubMed ID: 11986230
[TBL] [Abstract][Full Text] [Related]
9. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma.
Fonseca R; Hoyer JD; Aguayo P; Jalal SM; Ahmann GJ; Rajkumar SV; Witzig TE; Lacy MQ; Dispenzieri A; Gertz MA; Kyle RA; Greipp PR
Leuk Lymphoma; 1999 Nov; 35(5-6):599-605. PubMed ID: 10609798
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
13. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.
Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ
Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases.
Fonseca R; Witzig TE; Gertz MA; Kyle RA; Hoyer JD; Jalal SM; Greipp PR
Br J Haematol; 1998 May; 101(2):296-301. PubMed ID: 9609525
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant.
Laï JL; Michaux L; Dastugue N; Vasseur F; Daudignon A; Facon T; Bauters F; Zandecki M
Cancer Genet Cytogenet; 1998 Jul; 104(2):133-8. PubMed ID: 9666807
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.
Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Litzow MR; Henderson KJ; Van Wier SA; Ahmann GJ; Fonseca R
Blood; 2005 Oct; 106(8):2837-40. PubMed ID: 15976175
[TBL] [Abstract][Full Text] [Related]
17. PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
Sato K; Sakai H; Kato M; Nishio Y; Tsuruoka Y; Uemura Y; Yokoi S; Saito T; Matsunawa M; Suzuki Y; Isobe Y; Inoue Y; Takahashi M; Miura I
Int J Hematol; 2015 Jun; 101(6):608-11. PubMed ID: 25633778
[TBL] [Abstract][Full Text] [Related]
18. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Gran C; Uttervall K; Borg Bruchfeld J; Wallblom A; Alici E; Gahrton G; Nahi H
Eur J Haematol; 2019 Dec; 103(6):588-596. PubMed ID: 31487754
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic Study and Analysis of Protein Expression in Plasma Cell Myeloma with t(11;14)(q13;q32): Absence of BCL6 and SOX11, and Infrequent Expression of CD20 and PAX5.
Yokoi S; Sakai H; Uchida A; Uemura Y; Sato K; Tsuruoka Y; Nishio Y; Matsunawa M; Suzuki Y; Isobe Y; Kato M; Inoue Y; Hoshikawa M; Miura I
J Clin Exp Hematop; 2015; 55(3):137-43. PubMed ID: 26763361
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
